GERON CORP (GERN) 2.29 +0.07 (+3.15%)
2.29 +0.07 (+3.15%)
US3741631036 - Common Stock - After market: 2.28 -0.01 (-0.44%)
Fundamental Rating
Overall GERN gets a fundamental rating of 2 out of 10. We evaluated GERN against 631 industry peers in the Biotechnology industry. GERN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, GERN is valued expensive at the moment.
Profitability
Profitability Rating
GERN has negative profitability rations, so we won't be analyzing them here.
GERN's Return On Assets of -56.44% is worse than the rest of the industry. The industry average Return On Assets is -44.51%.
GERN's Profit Margin of -8563.80% is worse than the rest of the industry. The industry average Profit Margin is -464.10%. 89% of the industry peers have a better Profit Margin.
The Piotroski-F score of GERN is 2.00. This is a very weak score and indicates problems in health and profitability for GERN.
VS Industry
ROA (-56.44%) VS Industry: 37% outperformed.
-950.38
52.28
Profit Margin (-8563.8%) VS Industry: 11% outperformed.
-1,173,705.71
34,743.00
Valuation
Valuation Rating
With a price book ratio of 8.07, GERN is valued correctly.
GERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GERN. No positive earnings are expected for the next year.
When comparing the price book ratio of GERN to the average industry price book ratio of 1.67, GERN is valued more expensive than its industry peers. 92% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Book (8.07) VS Industry: 8% outperformed.
130.23
0.10
Growth
Growth Rating
The Revenue has grown by 277.59% in the past year. This is a very strong growth!
Based on estimates for the next 5 years, GERN will show a very strong growth in Revenue. The Revenue will grow by 813.01% on average per year.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
GERN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.09%.
Based on estimates for the next 5 years, GERN will show a small growth in Earnings Per Share. The EPS will grow by 3.36% on average per year.
The Revenue for GERN have been decreasing by -25.72% on average. This is quite bad
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -9.09% | -8.23% | -12.92% | 11.62% | 3.36% |
| Revenue | -25.72% | 9.19% | 277.59% | -10.99% | 117.99% | 531.8% | 813.01% |
Health
Health Rating
A Current Ratio of 2.68 indicates that GERN has no problem at all paying its short term obligations.
GERN has a Quick Ratio of 2.68. This indicates that GERN is financially healthy and has no problem in meeting its short term obligations.
Compared to an average industry Current Ratio of 6.18, GERN is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 6.05, GERN is worse placed to pay its short term obligations than its industry peers.
GERN has one of the worst Debt to Equity ratios in its industry. 87% of its industry peers require less debt for financing their operations.
Based on the Altman-Z score of -5.26, we must say that GERN is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.76, GERN is in worse financial health than its industry peers.
The Piotroski-F score of GERN is 2.00. This is a very weak score and indicates problems in health and profitability for GERN.
VS Industry
Debt/Equity (0.35) VS Industry: 13% outperformed.
15.37
0.00
Quick Ratio (2.68) VS Industry: 23% outperformed.
0.02
84.53
Current Ratio (2.68) VS Industry: 22% outperformed.
0.02
85.09
Altman-Z (-5.26) VS Industry: 27% outperformed.
-135.10
484.91
Dividend
Dividend Rating
No dividends for GERN!.
GERON CORP2.29
NASDAQ:GERN (11/28/2022, 7:00:01 PM)+0.07 (+3.15%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-03 2022-11-03/bmo | Earnings (Next) | 03-08 2023-03-08 |
| Ins Owners | 0.13% | Inst Owners | 49.56% |
| Market Cap | 873.03M | Analysts | 86.67 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 569.49 | P/B | 8.07 |
| EV/EBITDA | -4.47 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | 0% | Ex-Date | N/A |
| EPS 1Y | -9.09% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -25% |
| EPS Next Y | -8.23% | EPS Next 2Y | -12.92% |
| EPS Next 3Y | 11.62% | EPS Next 5Y | 3.36% |
| Revenue growth 1Y | 277.59% | Revenue growth 3Y | 9.19% |
| Revenue growth 5Y | -25.72% | Revenue growth Q2Q | 172.48% |
| Revenue Next Year | -10.99% | Revenue Next 2Y | 117.99% |
| Revenue Next 3Y | 531.8% | Revenue Next 5Y | 813.01% |
| Current Ratio | 2.68 | Quick Ratio | 2.68 |
| Altman-Z | -5.26 | F-Score | 2 |
| Debt/Equity | 0.35 | WACC | 9.21% |
| ROIC/WACC | N/A | ||
| ROA | -56.44% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | -8563.8% | OM | -8322.31% |
| Asset Turnover | 0.01 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA